Monte Rosa Therapeutics, Inc. Common Stock Share Price
NASDAQ: GLUEHealthcare
Live Monte Rosa Therapeutics, Inc. Common Stock Share Price Chart
O H L
Monte Rosa Therapeutics, Inc. Common Stock Performance Overview
Days Range
▼
$12.45Low
$12.55High
Markets Today
| Previous Close | $12.60 |
|---|---|
| Open | $12.55 |
| Volume | 180,229 |
| Day's Range | $12.45 - $12.55 |
| 52W Range | $6.16 - $25.77 |
| Market Cap | $1.08 B |
Historical Performance
| 1M Returns | -16.17 |
|---|---|
| 3M Returns | -31.19 |
| 6M Returns | -20.05 |
| 1Y Returns | +81.82 |
| 5Y Returns | -59.00 |
| 10Y Returns | NA |
Monte Rosa Therapeutics, Inc. Common Stock Fundamentals
| Market Cap | $1.08 B |
|---|---|
| Dividend yield | 0.00 |
| PE Ratio | 0.00 |
| PEG Ratio | N/A |
| Revenue | $123.67 M |
| ROE TTM | -0.17 |
| EPS TTM | $-1.74 |
| Quarterly Earnings Growth YOY | N/A |
| PB Ratio | 2.21 |
| EBITDA | $-45.85 M |
| Profit Margin | -31.23 |
| Market Cap | $1.08 B |
|---|---|
| Dividend yield | 0.00 |
| PE Ratio | 0.00 |
| PEG Ratio | N/A |
| Revenue | $123.67 M |
| ROE TTM | -0.17 |
| EPS TTM | $-1.74 |
|---|---|
| Quarterly Earnings Growth YOY | N/A |
| PB Ratio | 2.21 |
| EBITDA | $-45.85 M |
| Profit Margin | -31.23 |
Monte Rosa Therapeutics, Inc. Common Stock Profit & Loss
Quarterly
| Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|
| Total Revenue + | $84.93 M | $23.19 M | $12.77 M | $2.78 M | $4.21 M | $8.97 M |
| Gross Profit + | $84.93 M | $23.19 M | $12.77 M | $2.78 M | $4.21 M | $8.97 M |
| Operating Income | $44.04 M | -$15.55 M | -$32.98 M | -$49.72 M | -$50.03 M | -$49.13 M |
| EBITDA | $46.08 M | -$13.43 M | -$30.88 M | -$47.63 M | -$48.01 M | -$47.22 M |
| Interest Expense | $0 | $3.07 M | $0 | $0 | $0 | $5.92 M |
| Depreciation | $2.05 M | $2.13 M | $2.10 M | $2.09 M | $2.03 M | $1.91 M |
| Income Before Tax | $47.71 M | -$11.10 M | -$30.26 M | -$46.08 M | -$44.45 M | -$43.19 M |
| Income Tax Expense | $822.00 K | $1.20 M | -$3.18 M | $59.00 K | $52.00 K | $208.00 K |
| Net Income + | $46.88 M | -$12.29 M | -$27.08 M | -$46.13 M | -$44.50 M | -$43.40 M |
| Net Profit Margin | 55.2% | -53.01% | -212.1% | -1658.94% | -1057.08% | -483.91% |
Monte Rosa Therapeutics, Inc. Common Stock Financials Balance Sheet In USD
Quarterly
| Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|
| Share Capital | $6.00 K | $6.00 K | $6.00 K | $7.00 K | $8.00 K | $9.00 K |
| Reserve & Surplus | -$395.03 M | -$407.37 M | -$434.33 M | -$481.04 M | -$526.46 M | -$570.28 M |
| Non-Current Liabilities | $58.82 M | $49.65 M | $152.56 M | $151.39 M | $143.48 M | $144.22 M |
| Current Liabilities | $59.22 M | $41.85 M | $61.44 M | $64.21 M | $71.04 M | $59.66 M |
| Total Liabilities | $118.04 M | $91.51 M | $214.00 M | $215.60 M | $214.51 M | $203.88 M |
| Fixed Assets | $29.34 M | $29.05 M | $27.60 M | $25.99 M | $28.41 M | $29.93 M |
| Current Assets | $332.28 M | $299.46 M | $401.82 M | $393.19 M | $677.55 M | $631.41 M |
| Total Assets | $393.20 M | $359.59 M | $459.84 M | $448.66 M | $736.43 M | $691.16 M |
Monte Rosa Therapeutics, Inc. Common Stock Cash Flow
Quarterly
| Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|
| Net Income | $46.88 M | -$12.29 M | -$27.08 M | -$46.13 M | -$44.50 M | -$43.40 M |
| Operating Cash Flow | -$45.49 M | -$34.72 M | $100.43 M | -$43.01 M | -$37.37 M | -$44.11 M |
| Investing Cash Flow | -$100.23 M | $25.32 M | $38.14 M | -$65.07 M | -$261.00 M | -$28.86 M |
| Financing Cash Flow | $14.00 K | $365.00 K | $348.00 K | $29.62 M | $328.33 M | $3.21 M |
| Change in Cash | -$145.71 M | -$9.03 M | $138.91 M | -$78.46 M | $29.97 M | -$69.76 M |
Monte Rosa Therapeutics, Inc. Common Stock Return Calculator
The Monte Rosa Therapeutics, Inc. Common Stock stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.
Returns Estimator
Based on past performance of this fund
ENTER AMOUNT
$10,000
Select Duration
5Yrs
1 Yr5 Yrs
If you had invested $10,000 5 years ago, what would its value be today?$4,077
Invested Amount$10,000
Est. Returns$-5,923
About Monte Rosa Therapeutics, Inc. Common Stock
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
Popular Stocks
FAQs
What is the share price of Monte Rosa Therapeutics, Inc. Common Stock today?
Monte Rosa Therapeutics, Inc. Common Stock (GLUE) share price as of September 18, 2026 is $12.53. If you are investing from India, you can always check the valuation in the INR before investing.
Can Indian Investors purchase shares of Monte Rosa Therapeutics, Inc. Common Stock?
Yes, Indian Investors can invest in the Monte Rosa Therapeutics, Inc. Common Stock (GLUE) Share by opening an international trading account with Angel One.
How can I purchase Monte Rosa Therapeutics, Inc. Common Stock shares in India?
Purchasing Monte Rosa Therapeutics, Inc. Common Stock (GLUE) share from India can be done by: Directly: By opening an international trading account with Angel One. The process would include KYC verification. The account activation takes a few minutes to a few hours, after which you can start buying Monte Rosa Therapeutics, Inc. Common Stock (GLUE) by making deposits in US dollars. Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.
Can I buy Fractional shares of Monte Rosa Therapeutics, Inc. Common Stock?
Yes, you can purchase fractional shares of Monte Rosa Therapeutics, Inc. Common Stock (GLUE) or any other US company shares in Angel One for any dollar amount.
What is the market capitalization value of Monte Rosa Therapeutics, Inc. Common Stock?
The market capitalization of Monte Rosa Therapeutics, Inc. Common Stock on September 18, 2026, is $1.08 B.
In which sector Monte Rosa Therapeutics, Inc. Common Stock belongs?
Monte Rosa Therapeutics, Inc. Common Stock operates in the Healthcare sector, specifically in the Healthcare industry.
What documents are required to invest in Monte Rosa Therapeutics, Inc. Common Stock stocks?
In order to invest in Monte Rosa Therapeutics, Inc. Common Stock (GLUE) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.). From start to end, the process is digital and can be seamless.
Diversify Your Portfolio with US Stocks
Invest in Wall Street Giants from India
